Datasets:
Recag
/
C4_13

Dataset card Data Studio Files
xet
Community
text
stringlengths
9
72.5k
Phase II will be put out to bid early next month to ensure a seamless transition into the next phase of the project, the mayor’s office said.
Geniuses, no matter how smart or intimidating, still have some things in common with the rest of us.
Cumberbatch is no stranger to portraying individuals of remarkable intelligence, having taken on roles ranging from Star Trek‘s super-human Khan to Alan Turing in the upcoming film The Imitation Game.
“I suppose being remarkably stupid in comparison to any of these people’s abilities is difficult sometimes, but that only really manifests when you’re actually asked to do something that they can do,” says Cumberbatch.
For example? Playing the violin as Sherlock Holmes.
Above, watch Cumberbatch reflect on his past roles and what he relishes about the experiences.
Now, the case against the former Los Alamos scientist isn't even really about spying.
He'd failed the polygraph. That's what the FBI agents told him, anyway. So what if he said he was innocent? He was stonewalling, like Julius and Ethel Rosenberg, who were charged in 1951 with spying for the Soviets.
"The Rosenbergs are the only people that never cooperated with the federal government in an espionage case," one agent told Wen Ho Lee during an interrogation. "You know what happened to them? They electrocuted them, Wen Ho."
With that extraordinary threat, recounted in a declassified transcript of a March 7, 1999, FBI interview, investigators made it clear to the Los Alamos National Lab scientist that he was in deep trouble.
But Dr. Lee hadn't failed that now-long-ago lie-detector test. The FBI agents were lying, trying to elicit more response. And he won't be tried for spying. He's been charged with lesser, though serious, crimes.
Nearly two years after the matter began, this once-obscure researcher sits in jail, awaiting a trial this fall as his family asks for his release on bail. The case against Lee, meanwhile, has become the incredible shrinking investigation. Call it a post-cold-war spy case, in the sense that it's no longer overtly about espionage at all.
"I believe that if they had a stronger case they would have moved on it," says Steven Aftergood, director of the Project for Government Secrecy at the Federation of American Scientists. "As it is, I think they are charging Wen Ho Lee with more than they can prove."
This doesn't mean that Lee now appears a completely innocent victim. Even his supporters admit that some of his actions were wrong, even mysterious.
Why did he devote 40 hours to downloading nuclear data onto 10 computer tapes? What happened to most of the tapes? Why did he attempt entry into a classified area after his security privilege had been revoked - once at 3:30 a.m. on Christmas Eve?
Lee has offered no explanation. At one point, in his last 1999 FBI interview, he launched into a description of his teenage health problems to justify a 1988 memory lapse.
His lawyers depict him as something of a bumbling pack rat. They point out that he didn't bother to change the file names on some of the data at issue. He called the Los Alamos computer help desk for aid in moving some of the files.
"After four years of exhaustive investigation, the government has absolutely no evidence that Lee ever provided any information to any third party," said defense lawyer Mark Holscher at this week's bail hearings in Albuquerque, N.M.
And after three days of bail hearings this week, in which family and friends have pleaded for Lee's release on a multimillion-dollar bail bond, it is clear that even the importance of the information that Lee horded may remain at issue.
Early in the case, some investigators talked about the testing codes and other data on Lee's tapes as "crown jewels" of the nuclear era. This week, the assistant attorney general prosecuting Lee, George Stamboulidis, told a federal district-court judge that eventually "hundreds of millions of people could be killed" because of the scientist's actions.
But the defense was able to call a number of fellow nuclear experts who disputed whether the codes were important - and, indeed, whether they were even difficult to find.
An affidavit from Harold Agnew, a former director of the Los Alamos National Lab, said that the codes would be of little use to other nations for the development of their own weapons. "Further ... this information has been widely available in the open literature," read the affidavit.
The prosecution's case has been further damaged by its own missteps.
Prosecutors have emphasized that Lee failed to tell the FBI about a key 1988 meeting with Chinese scientists in a hotel room during an authorized trip to Beijing. Yet defense lawyers recently showed that Lee mentioned the meeting to his superiors in a written report on the trip.
And FBI agent Robert Messemer was forced this week to recant an assertion that Lee had lied when borrowing a colleague's computer to download his trove of data onto portable tapes. Lee had not, as Mr. Messemer first said, told the colleague he was simply going to write his rsum.
Is Lee the victim of selective prosecution because he is an Asian-American?
That is what Asian-American legal organizations assert. They say that recent congressional investigations into Chinese espionage and military development have created the climate that led to Lee's arrest.
And if Lee is granted bail now, after having been denied it on previous occasions, it will mean that the case against him is beginning to fall apart, some analysts say.
"To me, it would suggest some prosecutorial misconduct which might lead to eventual dismissal," says Mr. Aftergood.
Amazon Studios continues its expansion into genre programming with a first-look deal with “Game of Thrones” co-executive producer Vince Gerardis, the company announced Wednesday.
The deal gives Amazon access to Gerardis’ extensive intellectual property library that includes work from science fiction and fantasy authors like Robert Silverberg, David Brin, Greg Bear and Jack Vance. The plan is to use that IP to create new original series.
“Vince has his fingertips on a ‘library of worlds,’ and I’m excited about the prospects of building multiple series with him,” said Amazon Studios Head of Scripted Genre Programming Sharon Yguado in a statement.
Gerardis added that Amazon was a good fit for him because of its book business.
The two-time Emmy winner will produce the upcoming “Game of Thrones” spinoff series at HBO. Gerardis previously founded the literary management and production banner Created By, which was dedicated to developing and producing projects from his sci-fi and fantasy clients. Created By then merged with Startling, Inc, where Gerardis continues to develop large-scale, world-building IP.
The first-look deal announcement comes the day after Amazon revealed its first project under its deal with “Walking Dead” creator Robert Kirkman: an hour-long animated series based on Kirkman’s “Invincible” comics.
Borrowing just £50 more for a new car loan could save you more than £1,000 compared with a smaller loan, according to research by motoring consumer experts.
Analysis of some of the UK’s leading high street lenders suggests that borrowing the extra amount could save motorists between £175 and £1,600 over the course of a four-year repayment period.
And with research showing an eight per cent rise in car finance lending – to more than £10 billion – in the first half of 2018, there is scope for drivers to be saving themselves substantial amounts of cash.
According to the study by What Car? magazine, loans of £5,000 and above typically have lower interest rates than smaller loans. For example, the repayment total of a £5,000 loan from TSB over four years comes in around £1,300 cheaper than the repayment of a £4,950 loan over the same period.
The pattern is repeated at six more of the country’s biggest banks, with a massive £1,601 difference found between loans of £7,450 and £7,500 at Lloyds.
However, there is a cut-off point where bigger loans cease to offer better value. The study showed that above the £8,000 threshold loans would cost the customer more the more they borrow.
The Courteeners have announced details of a live show in the Preston 53 Degrees, set to take place on September 29.
The new date will precede the Manchester band’s previously-announced UK tour, set to kick off in Newcastle on October 3.
Tickets for the new date go on sale on Friday (July 18).
To check the availability of The Courteeners tickets and get all the latest listings, go to NME.COM/GIGS now, or call 0871 230 1094.
Federal prosecutors filed papers yesterday appealing a Manhattan judge’s decision criticizing the Justice Department and throwing out charges against a terror-probe suspect.
Judge Shira Scheindlin ruled on Wednesday that prosecutors had misused the material-witness law to jail Osama Awadallah, a 21-year-old San Diego student.
In her decision, the judge found prosecutors should not jail witnesses just because authorities fear they might commit a crime.
Since Sept. 11, an undisclosed number of people have been held as material witnesses by terror investigators.
The amazingly intelligent dolphins have been trained to perform a number of tricks and jumps and to participate in many of the fun and exciting activities dolphins love to do in an open-air theater.
Pick up from the hotel and Drop off by air-conditioned vehicle.
Drinks; Any personal expenses; Representative upon request; Gratuities (optional).
Available: Daily; Several shows per day.
(WASHINGTON, DC) -- On Thursday, September 19th, National Review and the Independent Women's Forum present the long-awaited Mad Women Debate: The Battle of the Sexes. The series debuts with an all-star panel of intrepid women including Kirsten Powers, Christina Hoff Sommers, Judy Bachrach, and Sabrina Schaeffer. Moderator is National Review Editor-at-Large Jonah Goldberg.
The debate beings at 6:30pm ET (wine & cheese at 6:00pm ET) at the Decatur House on Lafayette Square in Washington, D.C. With 300 tickets reserved the event will focus on whether there is a war on women or a war on men?
Lillian L. (DiStefano) DiGeronimo, 82, of Shrewsbury and West Palm Beach died on Wednesday March 25, 2009 in the JFK Hospital Atlantis Florida. Her husband Michael R. DiGeronimo Sr. died in 1993, and her son Michael R. DiGeronimo Jr. also predeceased her. Lillian is survived by her brother Mathew �Bob� DiStefano and his wife Betty of Worcester, and many nephews, nieces, and grandnephews, and grandnieces. She was also predeceased by two brothers, Salvatore and Paul DiStefano, and four sisters, Sandy Ferrara, Grace Ciccone, Millie Robillard, and Josephine Robillard.
Lillian was born in Worcester daughter of Salvatore and Angela (Gallo) DiStefano and lived in Shrewsbury most of her life. She and her husband were winter residents of Palm Beach for many years. Lillian worked as a bank teller before she retired. She was a long time active member of St. Anne�s Church and enjoyed her weekly card games with her friends. She was a great cook, and liked spending time at the casino. She will be missed dearly by her family and friends.
Lillian�s funeral will be held Wednesday from the MERCADANTE FUNERAL HOME & CHAPEL, 370 Plantation St. with a Mass of Christian burial at 10:00 AM in St. Anne�s Church, 130 Boston Turnpike. Calling hours will be held from 5-8 PM on Tuesday (tonight) in the funeral home. Interment will be in Mountain View Cemetery. Flowers may be sent or contributions made to St. Anne�s Church, 130 Boston Turnpike, Shrewsbury, MA 01545.
FULTON TWP, Lancaster County, Pa — State Police are investigating a bomb threat discovered on a note within the Swift Middle School in Solanco School District this morning. The note was discovered at approximately 11:35am. The school was evacuated and remains evacuated. The students are being transported via district transportation to the Solanco High School for release to their Guardians. The school notified families through the district’s alert program. The State Police release lists the adjacent Clermont Elementary School as being affected as well.
Both schools were searched and nothing was found. The schools will remain closed today.
CHAPEL HILL, N.C., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced its intention to offer and sell shares of its common stock with an aggregate public offering price of approximately $100 million in an underwritten public offering pursuant to its existing shelf registration statement. The company also intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering with an aggregate public offering price of approximately $15 million. The company intends to use the net proceeds from the offering to fund its research and development activities, including continued clinical and regulatory development of solithromycin in CABP and gonorrhea and Taksta in bone and joint infections, preparation for commercial readiness for solithromycin in CABP, working capital and general corporate and administrative expenses. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Morgan Stanley & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.
The securities described above are being offered by Cempra pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering. The offering may be made only by means of a prospectus, copies of which may be obtained, when available, from Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, telephone: 1-866-718-1649; or from Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 631-274-2806, Fax: 631-254-7140.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in Phase 3 clinical development for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin also recently entered a Phase 3 clinical trial for uncomplicated bacterial urethritis caused by Neisseria gonorrhoeae and chlamydia. Taksta™ (CEM-102) is Cempra's second product candidate, which is being developed for chronic oral treatment of staphylococcal infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.
Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: risks relating to the completion of the proposed public offering, including the satisfaction of customary closing conditions and the use of anticipated proceeds; the costs, timing, regulatory review and results of our studies and clinical trials and those of our strategic commercial partners; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our anticipated capital expenditures and our estimates regarding our capital requirements; our and our strategic commercial partners' ability to obtain FDA and foreign regulatory approval of our product candidates; the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties; the unpredictability of the size of the markets for, and market acceptance of, any of our products, including solithromycin and Taksta; our ability to produce and sell any approved products and the price we are able to realize for those products; our ability to retain and hire necessary employees and to staff our operations appropriately; our ability to compete in our industry; our dependence on the success of solithromycin and Taksta; innovation by our competitors; and our ability to stay abreast of and comply with new or modified laws and regulations that currently apply or become applicable to our business. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.
The Pharmaceutical Society of Australia (PSA) has welcomed the release of the initial draft of the National Pain Strategy.
PSA National Vice President and the only pharmacy representative on to the National Pain Summit Leaders' Meeting, Dr Lisa Nissen, said that PSA supported the intent of the draft strategy and looked forward to seeing the strategy finalised.
The Strategy aims to have pain management addressed as part of the Rudd Government's national health reforms. The draft strategy, the result of thousands of hours' work by more than 70 pain medicine specialists, other health professionals and consumers is now open for community and expert input.
'I believe the strategy has the capacity to lead to a collaborative approach being adopted, and that is a good thing. It was also good to see that the need for Quality use of Medicines in prescribing permeated the draft strategy,' she said The National Pain Strategy will be finalised at the National Pain Summit being held in Canberra on March 11, 2010.
- Chronic pain be recognised as a disease in its own right.
- Pain be given a diagnostic code along with other chronic diseases to document its prevalence, outcomes and costs.
- When monitoring patients, pain be included as the fifth vital sign (with blood pressure, heart rate, temperature and breathing rate).
- More effort be made to de-stigmatise pain (similar to the successful campaigns to de-stigmatise depression).
Chronic pain - defined as, constant daily pain for a period of three months or more - costs the economy an estimated $34.4 billion per annum or $10,847 per person affected, according to the MBF Foundation report The High Price of Pain conducted by Access Economics.
The report also found that more than 36.5 million working days were lost each year due to chronic pain, costing the economy and employers $11.7 billion annually in productivity losses.
The National Pain Summit is being organised by a Steering Committee with professional and consumer representation, under the leadership of the Australian and New Zealand College of Anaesthetists (ANZCA), the Faculty of Pain Medicine (FPM), the Australian Pain Society (APS) and consumer group, Chronic Pain Australia (CPA), in collaboration with the MBF Foundation and the Pain Management Research Institute.
Pharmaceutical Society of Australia. "Pharmaceutical Society Of Australia Supports Draft National Pain Strategy." Medical News Today. MediLexicon, Intl., 29 Oct. 2009. Web.
U.S. equity markets extended steep losses Wednesday after Chinese data delivered yet another blow to global markets, and oil prices plunged.
The Dow Jones Industrial Average dropped 251 points, or 1.47% to 16906. The S&P 500 shed 26 points, or 1.45%, to 1990, while the Nasdaq Composite eliminated 55 points, or 1.14% to 4835.
All 10 S&P 500 sectors were firmly in negative territory, as energy and materials led the way down.
Crumbling crude-oil prices weighed on market sentiment Wednesday after services data from China and the U.S. had investors on edge.
In recent action, West Texas Intermediate crude prices tumbled 5.56% to settle at $33.97 a barrel, the lowest since December 2008. Meanwhile, Brent, the international benchmark, dropped 6.01% to $34.23 a barrel, its lowest settlement value since June 2004.
The fresh drop in oil prices came after inventory update from the Energy Information Administration, which showed an unexpected drawdown in supplies, failed to boost the market as it was offset by significant builds in both gasoline and distillate inventories.
Crude stockpiles declined by 5.09 million barrels last week, while distillate stocks jumped by 6.31 million barrels, and gasoline stockpiles added 10.58 million barrels.
Also weighing on the price of the commodity were mounting tensions between Saudi Arabia and Iran, weak oil-demand figures from China, and developments out of North Korea. The nation, overnight, said it tested a hydrogen bomb.
Wayne Schmidt, chief investment officer at Gradient Investments, said the low oil-price story is likely to continue to be a theme throughout at least the first half of 2016.
The moves in oil weighed heavily on the energy sector, which was by far the biggest decliner of the 10 S&P 500 sectors, as Chevron alone (NYSE:CVX) clipped 28 points off the Dow Industrials.
Safe-haven assets including gold and Treasury bonds rose as investors looked to less-risky investments. Gold rose 1.16% during the session to $1,090 a troy ounce. The yield on the 10-year Treasury bond fell 0.060 percentage point to 2.190%. As yields fall, prices rise.
Meanwhile, silver declined 0.11% to $13.96 an ounce, while copper shed 0.41% to $2.09 a pound.
Global markets continued to be on edge after another onslaught of weak data overseas as global-growth worries plagued the markets.
On Monday, Chinese manufacturing data showed the tenth-straight month of contraction, while Wednesday brought another round of bleeding, this time thanks to weak service-sector data. The Caixin/Markit services PMI gauge dropped to a 17-month low to a reading of 50.2 last month. The gauge remains in expansion territory but is flirting with the 50 mark that separates growth from contraction.
Despite the weak data, China’s Shanghai Composite index ended up 2.25% partly due to a surge in resources shares, and as traders hoped a ban on large-scale asset sales would be extended as its six-month deadline nears on Friday. The ban was instituted after last summer’s global-market meltdown as investors and economists tried to put China’s slowing growth figures in context.
Elsewhere in Asia, markets closed to the downside. Hong Kong’s Hang Seng shed 0.98%, while Japan’s Nikkei dropped 0.99%.
Fear spread to European equity markets where shares tumbled. The Euro Stoxx 50, which tracks large-cap companies in the eurozone, dropped 1.25%. The French CAC 40 shed 1.30%, the German Dax declined 1.01%, and the UK’s FTSE 100 fell 1.06%.
Meanwhile, service-sector data was the name of the game in the U.S. Wednesday as well. The Institute for Supply-Management’s gauge of non-manufacturing activity in the nation unexpectedly fell to 55.3 in December from 55.9 the month prior. Wall Street had expected the gauge to tick up to 56.
Meanwhile, factory orders, the Commerce Department reported, slipped 0.2% in November, matching expectations.
Also on the economic calendar was the latest read on private-sector hiring last month. Payroll processor ADP reported that private-sector employment increased by 257,000 jobs, blowing past the 192,000 estimate. Traders paid close attention to ADP’s figures ahead of Friday’s all-important non-farm payrolls report.
The U.S. trade deficit narrowed more than expected in November to $42.37 billion from $44.48 billion the month prior. Wall Street expected the trade balance to shrink to $44 billion.
Finally, investors in the U.S. got an in-depth look at minutes from the Federal Open Market Committee’s December meeting. After two days of policy discussions between members last month, the FOMC opted to hike short-term interest rates from their near-zero range, the first increase in nearly a decade. The minutes will shed more light on the discussions between central bankers before they voted for the rate rise unanimously.
The minutes showed the decision was a “close call” for central bankers as they tried to balance the pros and cons of the dollar’s appreciation and low commodity prices and their effects on the U.S. economy. The minutes also showed that the central bank is committed to a gradual pace for future rate hikes.